Search company, investor...

Predict your next investment

Venture Capital
uaventurecap.com

Investments

14

Funds

3

About UAVenture Capital

UAVenture Capital is a venture capital fund designed to commercialize University of Arizona science, technology, services and products.

Headquarters Location

607 North 6th Ave

Tucson, Arizona, 85705,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest UAVenture Capital News

UAVenture Capital Portfolio Company StimAire Completes First-In-Human Study of Injectable Stimulator for Obstructive Sleep Apnea (OSA)

Oct 11, 2023

News provided by Share this article Share toX TUCSON, Ariz., Oct. 11, 2023 /PRNewswire/ -- Paradigm-shifting neuromodulation company, StimAire, has completed its first clinical trial in Australia. The first-in-human study tested a tiny injectable stimulator to treat obstructive sleep apnea (OSA). This study assessed the safety of the injection procedure, the operation of the patented device, and the feasibility of the approach. In addition, the first overnight sleep studies were conducted of an OSA patient with and without the StimAire device modulating the hypoglossal nerve throughout the night. There were no adverse events during the study. Furthermore, no significant pain or discomfort was experienced from the injection procedures. Efficacy results from the sleep studies of the OSA patient, as measured by obstructive events, were as expected. Furthermore, this patient slept 2.5 times longer with our device than without it and enjoyed 30 minutes of REM sleep vs. none without it. Robert Dean PhD MD/ENT, StimAire Chief Clinical Officer, said, "After developing this injection procedure for StimAire at the University of Arizona College of Medicine, I was delighted to see these results. This technology has the potential to move treatments like this from the operating room to the doctor's office, lowering the cost of care and enabling immediate recovery." StimAire's device modulates peripheral nerves, like the hypoglossal, using a tiny, battery-free, injectable receiver/stimulator activated by a small wearable. StimAire's system can be built with readily available components, expediting the path to production. The tiny injectable is placed in close proximity to the nerve through a 17-gauge needle under ultrasound guidance. Tarek Makansi PhD EE, President and CTO of StimAire, said "We are grateful to this team for advancing non-surgical treatments that stimulate peripheral nerves. The ultimate goals are replacement of pacemaker-like devices and universal access to advanced treatments." Fletcher McCusker, Managing Director of UAVenture Capital, StimAire's lead investor, said "Of our entire portfolio we are the most excited about the progress of StimAire. Comparable devices have to be surgically implanted. The StimAire office-based injectable design has achieved encouraging early results for the treatment of OSA. We are honored to invest in the world-changing technology." About StimAire StimAire is a venture-backed medical device company located in Tucson, AZ USA. StimAire's efforts are focused on enabling injectability for neuromodulation devices in order to make "electricity as medicine" readily available and reimbursable world-wide. StimAire has partnered with the University of Arizona College of Medicine – Tucson through the Sponsored Research Program for its preclinical work with Physiology Professors Fiona Bailey, Andrew Fuglevand, and others. StimAire is funded by UAVenture Capital, the Desert Angels, and individual investors. About UAVenture Capital UAVenture Capital Fund LLC, or UAVC, is a Tucson-based investment fund designed specifically to help finance University of Arizona connected enterprises.

UAVenture Capital Investments

14 Investments

UAVenture Capital has made 14 investments. Their latest investment was in Freefall Aerospace as part of their Unattributed VC on October 10, 2023.

CBI Logo

UAVenture Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/10/2023

Unattributed VC

Freefall Aerospace

$1.3M

Yes

1

9/1/2023

Series A

Delta Development Team

$0.96M

Yes

2

4/22/2020

Series A

CMLaser Technologies

Yes

1

11/18/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/2/2019

Seed VC

Subscribe to see more

Subscribe to see more

10

Date

10/10/2023

9/1/2023

4/22/2020

11/18/2019

10/2/2019

Round

Unattributed VC

Series A

Series A

Series A

Seed VC

Company

Freefall Aerospace

Delta Development Team

CMLaser Technologies

Subscribe to see more

Subscribe to see more

Amount

$1.3M

$0.96M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

1

10

10

UAVenture Capital Fund History

3 Fund Histories

UAVenture Capital has 3 funds, including UAVenture Capital Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/30/2019

UAVenture Capital Fund II

Early-Stage Venture Capital

Open

$13.97M

1

8/16/2018

UAVenture Capital Fund LLC

Subscribe to see more

Subscribe to see more

$99M

10

9/28/2017

UAVenture Capital

10

Closing Date

4/30/2019

8/16/2018

9/28/2017

Fund

UAVenture Capital Fund II

UAVenture Capital Fund LLC

UAVenture Capital

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Open

Subscribe to see more

Amount

$13.97M

$99M

Sources

1

10

10

UAVenture Capital Team

1 Team Member

UAVenture Capital has 1 team member, including current Founder, Chief Executive Officer, Fletcher J. McCusker.

Name

Work History

Title

Status

Fletcher J. McCusker

Founder, Chief Executive Officer

Current

Name

Fletcher J. McCusker

Work History

Title

Founder, Chief Executive Officer

Status

Current

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.